Q3 25 EPS
$0.75
BEAT +5.09%
Est. $0.71
Q3 25 Revenue
$5.07B
BEAT +1.83%
Est. $4.97B
vs S&P Since Q3 25
-54.0%
TRAILING MARKET
BSX -46.1% vs S&P +7.9%
Market Reaction
Did BSX Beat Earnings? Q3 2025 Results
Boston Scientific delivered a standout third quarter for fiscal 2025, posting adjusted EPS of $0.75 and revenue of $5.07 billion, beating consensus estimates of $0.71 and $4.97 billion by 5.09% and 1.83%, respectively, while revenue climbed 20.3% yea… Read more Boston Scientific delivered a standout third quarter for fiscal 2025, posting adjusted EPS of $0.75 and revenue of $5.07 billion, beating consensus estimates of $0.71 and $4.97 billion by 5.09% and 1.83%, respectively, while revenue climbed 20.3% year over year and topped the company's own guidance range. The primary engine behind the quarter's strength was the Cardiovascular segment, where Cardiology sales of $2.64 billion grew 24.0% on a reported basis, fueled by the continued global rollout of the FARAPULSE pulsed field ablation system, including expanded labeling in Japan; electrophysiology sales alone surged 63% in the quarter, reinforcing the company's momentum in pulsed field ablation technology. The U.S. Led geographically with $3.29 billion in sales, up 27.0%, while EMEA lagged at just 2.6% reported growth. Looking ahead, Boston Scientific guided Q4 adjusted EPS to $0.77 to $0.79 and full-year 2025 adjusted EPS to $3.02 to $3.04, with organic revenue growth of approximately 15.5% expected for the full year.
Key Takeaways
- • Cardiovascular segment organic growth of 19.4% driven by strong Cardiology performance
- • U.S. region grew 27.0% driving majority of overall growth
- • FARAPULSE pulsed field ablation system continued global expansion
- • Urology growth of 28.1% boosted by acquisitions
BSX YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
BSX Revenue by Segment
With YoY comparisons, source: SEC Filings
BSX Revenue by Geography
With YoY comparisons, source: SEC Filings
“We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team.”
— Mike Mahoney, Q3 2025 Earnings Press Release
BSX Earnings Trends
BSX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BSX EPS Trend
Earnings per share: estimate vs actual
BSX Revenue Trend
Quarterly revenue: estimate vs actual
BSX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $0.80 | — | $5.20B | +0.60% |
| Q4 25 BEAT FY | $0.78 | $0.80 | +2.56% | $5.29B | +0.04% |
| FY Full Year | $3.04 | $3.06 | +0.80% | $20.07B | +0.01% |
| Q3 25 BEAT | $0.71 | $0.75 | +5.09% | $5.07B | +1.83% |
| Q2 25 BEAT | $0.73 | $0.75 | +3.42% | $5.06B | +3.39% |
| Q1 25 BEAT | $0.67 | $0.75 | +11.52% | $4.66B | +1.98% |